Eurobio Scientific Société anonyme (ALERS.PA)
EUR 23.8
(-5.93%)
EUR 23.8
(-5.93%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 18.98 Million EUR | -42.59% |
| 2022 | 40.49 Million EUR | -49.21% |
| 2021 | 79.63 Million EUR | -9.49% |
| 2020 | 88.56 Million EUR | 1171.59% |
| 2019 | 6.93 Million EUR | 208.63% |
| 2018 | 4.34 Million EUR | 2193.88% |
| 2017 | -2.58 Million EUR | 101.98% |
| 2016 | -4.95 Million EUR | 18.37% |
| 2015 | -4.29 Million EUR | -80.57% |
| 2014 | -3.36 Million EUR | 27.86% |
| 2013 | -4.65 Million EUR | 26.99% |
| 2012 | -6.38 Million EUR | 12.93% |
| 2011 | -6.07 Million EUR | -16.95% |
| 2010 | -6.26 Million EUR | 29.59% |
| 2009 | -8.9 Million EUR | 18.59% |
| 2008 | -10.93 Million EUR | -50.65% |
| 2007 | -7.25 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 11.49 Million EUR | 0.0% |
| 2023 Q4 | 12.21 Million EUR | 0.0% |
| 2023 FY | - EUR | -42.59% |
| 2023 Q2 | 9.62 Million EUR | 0.0% |
| 2022 Q2 | 25.94 Million EUR | 0.0% |
| 2022 FY | - EUR | -49.21% |
| 2022 Q4 | 14.61 Million EUR | 0.0% |
| 2021 Q4 | 35.89 Million EUR | 0.0% |
| 2021 FY | - EUR | -9.49% |
| 2021 Q2 | 43.96 Million EUR | 0.0% |
| 2020 FY | - EUR | 1171.59% |
| 2020 Q4 | 69.35 Million EUR | 0.0% |
| 2020 Q2 | 21.7 Million EUR | 0.0% |
| 2019 FY | - EUR | 208.63% |
| 2019 Q2 | 4.04 Million EUR | 0.0% |
| 2019 Q4 | 5.73 Million EUR | 0.0% |
| 2018 Q4 | -660 Thousand EUR | 0.0% |
| 2018 Q2 | 2.9 Million EUR | 0.0% |
| 2018 FY | - EUR | 2193.88% |
| 2017 Q4 | 584 Thousand EUR | 0.0% |
| 2017 FY | - EUR | 101.98% |
| 2017 Q2 | -486 Thousand EUR | 0.0% |
| 2016 Q2 | -3.04 Million EUR | 0.0% |
| 2016 FY | - EUR | 18.37% |
| 2016 Q4 | -1.91 Million EUR | 0.0% |
| 2015 Q4 | -3.55 Million EUR | 0.0% |
| 2015 Q2 | -2.51 Million EUR | 0.0% |
| 2015 FY | - EUR | -80.57% |
| 2014 Q2 | -944 Thousand EUR | 0.0% |
| 2014 Q4 | -2.41 Million EUR | 0.0% |
| 2014 FY | - EUR | 27.86% |
| 2013 Q4 | -2.56 Million EUR | 0.0% |
| 2013 Q2 | -2.09 Million EUR | 0.0% |
| 2013 FY | - EUR | 26.99% |
| 2012 Q2 | - EUR | 100.0% |
| 2012 FY | - EUR | 12.93% |
| 2012 Q4 | - EUR | 100.0% |
| 2012 Q3 | -1.64 Million EUR | 0.0% |
| 2012 Q1 | -1.64 Million EUR | 0.0% |
| 2011 Q4 | - EUR | 100.0% |
| 2011 Q2 | - EUR | 100.0% |
| 2011 FY | - EUR | -16.95% |
| 2011 Q3 | -2.05 Million EUR | 0.0% |
| 2011 Q1 | -2.05 Million EUR | 0.0% |
| 2010 Q1 | -2.26 Million EUR | 0.0% |
| 2010 FY | - EUR | 29.59% |
| 2010 Q4 | - EUR | 100.0% |
| 2010 Q3 | -2.26 Million EUR | 0.0% |
| 2010 Q2 | - EUR | 100.0% |
| 2009 Q1 | -2.32 Million EUR | 15.41% |
| 2009 Q4 | - EUR | 100.0% |
| 2009 Q3 | -2.32 Million EUR | 0.0% |
| 2009 Q2 | -2.32 Million EUR | 0.0% |
| 2009 FY | - EUR | 18.59% |
| 2008 FY | - EUR | -50.65% |
| 2008 Q1 | -2.75 Million EUR | -37.42% |
| 2008 Q2 | -2.75 Million EUR | 0.0% |
| 2008 Q3 | -2.75 Million EUR | 0.0% |
| 2008 Q4 | -2.75 Million EUR | 0.0% |
| 2007 Q4 | -2 Million EUR | 0.0% |
| 2007 Q2 | -2 Million EUR | 0.0% |
| 2007 Q3 | -2 Million EUR | 0.0% |
| 2007 Q1 | -2 Million EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Affluent Medical SA | -13.34 Million EUR | 242.292% |
| Bluelinea Société Anonyme | -323.98 EUR | 5860338.286% |
| Carmat SA | -50.45 Million EUR | 137.632% |
| Diagnostic Medical Systems S.A. | -7.05 Million EUR | 369.038% |
| Euromedis Groupe | -4.43 Million EUR | 528.076% |
| Ikonisys S.A. | -2.34 Million EUR | 908.766% |
| Implanet S.A. | -5.07 Million EUR | 473.961% |
| Median Technologies SA | -19.58 Million EUR | 196.942% |
| SpineGuard SA | -3.49 Million EUR | 642.95% |
| Theraclion SA | -4.48 Million EUR | 523.111% |
| Euroapi S.A. | -155.39 Million EUR | 112.218% |
| Guerbet SA | 98.83 Million EUR | 80.791% |
| Ion Beam Applications SA | 12.53 Million EUR | -51.524% |
| Koninklijke Philips N.V. | 1.04 Billion EUR | 98.176% |
| Sequana Medical NV | -29.13 Million EUR | 165.161% |